Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
558
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis

Douglas TremblayTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0003-2584-6953
ORCID Icon,
Amber KingLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
,
Lihua LiDepartment of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Erin MoshierDepartment of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Alexander ColtoffTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Anita KoshyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Marina KremyanskayaTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Ronald HoffmanTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;
,
Michael J. MauroLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
,
Raajit K. RampalLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
&
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Correspondence[email protected]
 show all
Pages 660-667 | Received 03 Sep 2019, Accepted 23 Oct 2019, Published online: 12 Nov 2019

References

  • United States Food and Drug Administration. JAKAFI (Ruxolitinib) Label. Silver Spring (MD): USFDA; 2011.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
  • Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol. 2016;95(2):361–362.
  • Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95(7):1207–1209.
  • Sylvine P, Thomas S, Pirayeh E, et al. Infections associated with ruxolitinib: study in the French Pharmacovigilance database. Ann Hematol. 2018;97(5):913–914.
  • Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202.
  • Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–3844.
  • Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694–706.
  • Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707.
  • Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347.
  • Polverelli N, Breccia M, Benevolo G, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92(1):37–41.
  • Ritchie EK, Krichevsky S, Roboz GJ, et al. Incidence of infections and second cancers in Philadelphia chromosome-negative patients with myeloproliferative neoplasms treated with ruxolitinib. American Society of Hematology 59th Annual Meeting and Exposition; 2017 Dec 7–13; Atlanta, GA. Vol. 130.
  • White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Statist Med. 2011;30(4):377–399.
  • Raghunathan T, Solenberger P, Hoewyk J. IVEware: Imputation and Variance Estimation Software (Version 0.3): complete user guide. Ann Arbor: Survey Research Center, University of Michigan; 2007.
  • Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496.
  • Yuan YC. Multiple imputation for missing data: concepts and new developments. Rockville (MD): SAS Institute Inc.; 2000.
  • Al-Ali HK, Griesshammer M, Le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065–1073.
  • Breccia M, Andriani A, Montanaro M, et al. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol. 2017;96(3):387–391.
  • Chen YY, Huang CE, Lee KD, et al. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: a single institution experience in Taiwan. Hematology. 2016;21(1):3–9.
  • Ellis MH, Lavi N, Mishchenko E, et al. Ruxolitinib treatment for myelofibrosis: efficacy and tolerability in routine practice. Leuk Res. 2015;39(11):1154–1158.
  • Komatsu N, Kirito K, Shimoda K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol. 2017;105(3):309–317.
  • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435.
  • Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015;33(20):2288–2295.
  • Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019;133(21):2348.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.